Bestopick Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.98 M
- Company Age 15 Year, 7 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 82.45%
- Profit Growth 37.88%
- Ebitda -3.32%
- Net Worth -10.11%
- Total Assets -1.67%
About Bestopick Life Sciences
Bestopick Life Sciences Private Limited (BLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 February 2010 and has a history of 15 years. Its registered office is in Ghaziabad, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.98 M, as per Ministry of Corporate Affairs (MCA) records.
Suman Lata and Niketa Tyagi serve as directors at the Company.
Company Details
-
Location
Ghaziabad, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233UP2010PTC039426
-
Company No.
039426
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Feb 2010
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Bestopick Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suman Lata
|
Director | 21-Aug-2019 | Current |
|
Niketa Tyagi
|
Director | 11-Jun-2021 | Current |
Financial Performance of Bestopick Life Sciences.
Bestopick Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 82.45% increase. The company also saw a substantial improvement in profitability, with a 37.88% increase in profit. The company's net worth observed a substantial decline by a decrease of 10.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bestopick Life Sciences?
In 2021, Bestopick Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Omex Biotech Private LimitedSuman Lata and Niketa Tyagi are mutual person
-
Uniplus Biotech Private Limited
Suman Lata and Niketa Tyagi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bestopick Life Sciences?
Unlock and access historical data on people associated with Bestopick Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bestopick Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bestopick Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
